Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) management will conduct a conference call for 10th August 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.sppirx.com
Earnings Expectation
Spectrum Pharmaceuticals, Inc. is reporting second quarter earnings results on Monday 10th August 2020, after market close. The consensus estimates from Thomson Reuters are loss of $ 0.32 per share. For the full year, analysts predict revenues of $ 4.06 million, while looking forward to loss of $ 1.36 per share.
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkins lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients.
